Tag Archives: European Medicines Agency

The Year to Come: EMA's Plans Announced

By Clark Herman | Published: December 20, 2012
At the end of last month, the European Medicines Agency approved its budget and work program for the coming year, promising to implement measures to increase operational efficiency, enhance transparency and communication with stakeholders, and improve the quality and consistency of rulemaking. With a 4.1% increase in budget to €231.6 million and an anticipated 54 [...]
Posted in Europe, Regulatory, Safety, Strategy | Also tagged , , | Leave a comment

Europe: Health Commissioner's Sudden Exit Spotlights Regulation Crisis

By Guest Blogger | Published: October 24, 2012
The sudden departure of EC Health Commissioner John Dalli tops an already difficult year for the European pharma regulators, writes Reflector. The abrupt departure of Health Commissioner John Dalli in highly controversial circumstances comes on top of an extremely difficult year for the European Medicines Agency (EMA). At the same time, one of the main supervisory bodies [...]
Posted in Strategy | Also tagged , , | Leave a comment

Exclusive Interview: The European Medicine Agency's Thomas Lönngren

By William Looney | Published: December 14, 2010
The European Medicines Agency (EMA) is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs. In return, EMA has made a virtue of necessity. It filled the regulatory [...]
Posted in Europe, Global, People, Regulatory, leadership | Also tagged , , , | 2 Comments

HTA Concerns From European Drug Agency

By Julian Upton | Published: June 18, 2010
The EMA’s Thomas Lönngren has gone public with his disquiet over organizations such as NICE. But pharma still needs more allies in fighting what it sees as the failings of the health technology assessment bodies, says Pharm Exec Europe’s Brussels correspondent, Reflector. Europe’s pharmaceutical firms were never very keen on Britain’s influential National Institute for Health [...]
Posted in Europe, Global, Guest Blog, Regulatory, Safety, Strategy | Also tagged , , , | Leave a comment